000			02145 a2200613 4500
005			20250514190616.0
264		0	_c20050721
008			200507s 0 0 eng d
022			_a1744-7623
024	7		_a10.1517/eoed.9.1.155.32952 _2doi
040			_aNLM _beng _cNLM
100	1		_aHolst, Jens Juul
245	0	0	_aTreatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. _h[electronic resource]
260			_bExpert opinion on emerging drugs _cMay 2004
300			_a155-66 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdenosine Deaminase _xphysiology
650	0	4	_aAdenosine Deaminase Inhibitors
650	0	4	_aAfferent Pathways _xphysiology
650	0	4	_aAnimals
650	0	4	_aAppetite _xdrug effects
650	0	4	_aDiabetes Mellitus, Experimental _xdrug therapy
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDipeptidyl Peptidase 4 _xphysiology
650	0	4	_aDrug Therapy, Combination
650	0	4	_aExenatide
650	0	4	_aGlucagon _xagonists
650	0	4	_aGlucagon-Like Peptide 1
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aGlycoproteins _xantagonists & inhibitors
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xadministration & dosage
650	0	4	_aHypothalamus _xdrug effects
650	0	4	_aInsulin _xbiosynthesis
650	0	4	_aInsulin Secretion
650	0	4	_aIntestinal Mucosa _xinnervation
650	0	4	_aIslets of Langerhans _xdrug effects
650	0	4	_aLiraglutide
650	0	4	_aLizards
650	0	4	_aMaleimides _xtherapeutic use
650	0	4	_aMice
650	0	4	_aMice, Knockout
650	0	4	_aMice, Obese
650	0	4	_aPeptide Fragments _xagonists
650	0	4	_aPeptides _xpharmacology
650	0	4	_aProglucagon
650	0	4	_aProtein Precursors _xagonists
650	0	4	_aRats
650	0	4	_aRats, Zucker
650	0	4	_aReceptors, Glucagon _xagonists
650	0	4	_aVenoms _xpharmacology
773	0		_tExpert opinion on emerging drugs _gvol. 9 _gno. 1 _gp. 155-66
856	4	0	_uhttps://doi.org/10.1517/eoed.9.1.155.32952 _zAvailable from publisher's website
999			_c14863724 _d14863724